122 related articles for article (PubMed ID: 9535996)
1. Intravenous and oral l-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans.
Walsh SL; Johnson RE; Cone EJ; Bigelow GE
J Pharmacol Exp Ther; 1998 Apr; 285(1):71-82. PubMed ID: 9535996
[TBL] [Abstract][Full Text] [Related]
2. Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
Eissenberg T; Stitzer ML; Bigelow GE; Buchhalter AR; Walsh SL
J Pharmacol Exp Ther; 1999 May; 289(2):936-45. PubMed ID: 10215673
[TBL] [Abstract][Full Text] [Related]
3. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance.
Houtsmuller EJ; Walsh SL; Schuh KJ; Johnson RE; Stitzer ML; Bigelow GE
J Pharmacol Exp Ther; 1998 May; 285(2):387-96. PubMed ID: 9580575
[TBL] [Abstract][Full Text] [Related]
4. l-alpha-Acetylmethadol, l-alpha-acetyl-N-normethadol and l-alpha-acetyl-N,N-dinormethadol: comparisons with morphine and methadone in suppression of the opioid withdrawal syndrome in the dog.
Vaupel DB; Jasinski DR
J Pharmacol Exp Ther; 1997 Nov; 283(2):833-42. PubMed ID: 9353405
[TBL] [Abstract][Full Text] [Related]
5. Chronic l-alpha acetylmethadol in rhesus monkeys: discriminative stimulus and other behavioral measures of dependence and withdrawal.
Brandt MR; France CP
J Pharmacol Exp Ther; 1998 Dec; 287(3):1029-37. PubMed ID: 9864289
[TBL] [Abstract][Full Text] [Related]
6. Chronic l-alpha-acetylmethadol (LAAM) in rhesus monkeys: tolerance and cross-tolerance to the antinociceptive, ventilatory, and rate-decreasing effects of opioids.
Brandt MR; France CP
J Pharmacol Exp Ther; 2000 Jul; 294(1):168-78. PubMed ID: 10871309
[TBL] [Abstract][Full Text] [Related]
7. Changes in sensitivity to the rate-decreasing effects of opioids in pigeons treated acutely or chronically with l-alpha-acetylmethadol.
Gerak LR; France CP
J Pharmacol Exp Ther; 1997 May; 281(2):799-809. PubMed ID: 9152388
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.
Wolstein J; Gastpar M; Finkbeiner T; Heinrich C; Heitkamp R; Poehlke T; Scherbaum N
Pharmacopsychiatry; 2009 Jan; 42(1):1-8. PubMed ID: 19153939
[TBL] [Abstract][Full Text] [Related]
9. Developmental toxicity of levo-alpha-acetylmethadol (LAAM) in tolerant rats.
York RG; Denny KH; Moody DE; Alburges ME
Int J Toxicol; 2002; 21(2):147-59. PubMed ID: 12022632
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Kharasch ED; Whittington D; Hoffer C; Krudys K; Craig K; Vicini P; Sheffels P; Lalovic B
Clin Pharmacokinet; 2005; 44(7):731-51. PubMed ID: 15966756
[TBL] [Abstract][Full Text] [Related]
11. The effects of levo-alpha-acetylmethadol and its metabolites on schedule-controlled behavior in the pigeon.
McGivney WT; McMillan DE
J Pharmacol Exp Ther; 1981 Feb; 216(2):299-305. PubMed ID: 7463351
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.
Rook EJ; van Ree JM; van den Brink W; Hillebrand MJ; Huitema AD; Hendriks VM; Beijnen JH
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):86-96. PubMed ID: 16433897
[TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus effects of l-alpha-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys.
Brandt MR; Cabansag SR; France CP
J Pharmacol Exp Ther; 1997 Aug; 282(2):574-84. PubMed ID: 9262317
[TBL] [Abstract][Full Text] [Related]
14. [New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
Petersen H; Skauge L; Svejsø J; Ege PP
Ugeskr Laeger; 2000 Nov; 162(48):6553-6. PubMed ID: 11187226
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis.
Newcombe DA; Bochner F; White JM; Somogyi AA
Drug Alcohol Depend; 2004 Oct; 76(1):63-72. PubMed ID: 15380290
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of l-alpha-acetylmethadol in the rat.
Henderson GL; North-Root H; Kuttab SH
Drug Metab Dispos; 1977; 5(4):321-8. PubMed ID: 19211
[TBL] [Abstract][Full Text] [Related]
18. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.
Moody DE; Walsh SL; Rollins DE; Neff JA; Huang W
Clin Pharmacol Ther; 2004 Aug; 76(2):154-66. PubMed ID: 15289792
[TBL] [Abstract][Full Text] [Related]
19. The use of levo-alpha-acetylmethadol (LAAM) in methadone patients who have not achieved heroin abstinence.
Borg L; Ho A; Wells A; Joseph H; Appel P; Moody D; Kreek MJ
J Addict Dis; 2002; 21(3):13-22. PubMed ID: 12094997
[TBL] [Abstract][Full Text] [Related]
20. Cross-tolerance and mu agonist efficacy in pigeons treated with LAAM or buprenorphine.
Galici R; McMahon LR; France CP
Pharmacol Biochem Behav; 2005 Jul; 81(3):626-34. PubMed ID: 15946731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
